



# MADAGASCAR

Number of new cases

**21 297**

Number of deaths

**14 270**

Number of prevalent cases (5-year)

**43 976**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	14 559 756	14 618 319	29 178 075
<b>Incidence*</b>			
Number of new cancer cases	8 500	12 797	21 297
Age-standardized incidence rate	104.9	130.7	117.4
Risk of developing cancer before the age of 75 years (cum. risk %)	10.9	13.0	11.9
Top 3 leading cancers (ranked by cases)**	Prostate Liver NHL	Cervix uteri Breast Colorectum	Cervix uteri Breast Prostate
<b>Mortality*</b>			
Number of cancer deaths	6 048	8 222	14 270
Age-standardized mortality rate	78.9	89.2	83.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.1	9.2	8.6
Top 3 leading cancers (ranked by deaths)**	Prostate Liver Oesophagus	Cervix uteri Breast Liver	Cervix uteri Breast Prostate
<b>Prevalence*</b>			
5-year prevalent cases	16 008	27 968	43 976



## Top 5 most frequent cancers\*\*

**Males**




Total: 8 500

Rank	Cancer site	Number of cases	Percent
1st	Prostate	2 160	25.4%
2nd	Liver	621	7.3%
3rd	NHL	483	5.7%
4th	Oesophagus	459	5.4%
5th	Colorectum	416	4.9%
-	Others	4 361	51.3%

Number of new cases in 2022, males, all ages

**Females**




Total: 12 797

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	4 060	31.7%
2nd	Breast	2 875	22.5%
3rd	Colorectum	526	4.1%
4th	Liver	451	3.5%
5th	NHL	422	3.3%
-	Others	4 463	34.9%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 21 297

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	4 060	19.1%
2nd	Breast	2 875	13.5%
3rd	Prostate	2 160	10.1%
4th	Liver	1 072	5.0%
5th	Colorectum	942	4.4%
-	Others	10 188	47.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	4 060	1	19.1	4.4	2 690	1	18.9	3.3	9 135	20.8
Breast	2 875	2	13.5	3.3	1 498	2	10.5	1.8	6 473	14.7
Prostate	2 160	3	10.1	3.8	1 404	3	9.8	2.4	3 567	8.1
Liver	1 072	4	5.0	0.58	985	4	6.9	0.56	1 798	4.1
Colorectum	942	5	4.4	0.63	664	5	4.7	0.46	1 921	4.4
NHL	905	6	4.2	0.37	474	9	3.3	0.23	2 167	4.9
Bladder	776	7	3.6	0.58	438	10	3.1	0.32	1 683	3.8
Oesophagus	683	8	3.2	0.48	621	6	4.4	0.46	1 078	2.5
Stomach	670	9	3.1	0.52	601	7	4.2	0.47	1 022	2.3
Leukaemia	667	10	3.1	0.27	476	8	3.3	0.23	1 504	3.4
Lip, oral cavity	383	11	1.8	0.24	254	12	1.8	0.17	806	1.8
Lung	335	12	1.6	0.24	305	11	2.1	0.23	521	1.2
Ovary	267	13	1.3	0.31	190	15	1.3	0.26	567	1.3
Kidney	261	14	1.2	0.07	168	16	1.2	0.06	648	1.5
Brain CNS	257	15	1.2	0.10	213	13	1.5	0.09	665	1.5
Pancreas	206	16	0.97	0.15	202	14	1.4	0.15	268	0.61
Vulva	206	16	0.97	0.18	116	18	0.81	0.12	510	1.2
Oropharynx	193	18	0.91	0.11	117	17	0.82	0.07	485	1.1
Thyroid	189	19	0.89	0.11	70	23	0.49	0.05	439	1.00
Melanoma	176	20	0.83	0.12	78	20	0.55	0.05	409	0.93
Hodgkin lymphoma	164	21	0.77	0.06	74	22	0.52	0.03	416	0.95
Corpus uteri	158	22	0.74	0.25	53	26	0.37	0.08	392	0.89
Hypopharynx	127	23	0.60	0.09	109	19	0.76	0.08	152	0.35
Larynx	114	24	0.54	0.08	75	21	0.53	0.06	288	0.66
Salivary glands	102	25	0.48	0.06	60	25	0.42	0.04	241	0.55
Nasopharynx	97	26	0.46	0.05	68	24	0.48	0.04	212	0.48
Multiple myeloma	57	27	0.27	0.04	48	27	0.34	0.03	121	0.28
Vagina	54	28	0.25	0.05	34	28	0.24	0.04	101	0.23
Testis	26	29	0.12	0.02	10	31	0.07	0.02	68	0.16
Gallbladder	24	30	0.11	0.02	24	29	0.17	0.02	33	0.08
Mesothelioma	14	31	0.07	0.01	13	30	0.09	0.01	23	0.05
Penis	9	32	0.04	0.02	4	32	0.03	0.00	20	0.05
<b>All cancers</b>	<b>21 297</b>	-	-	<b>11.9</b>	<b>14 270</b>	-	-	<b>8.6</b>	<b>43 976</b>	-
<b>All cancers excl. NMSC</b>	<b>20 693</b>	-	-	<b>11.7</b>	<b>14 034</b>	-	-	<b>8.5</b>	<b>42 428</b>	-

Data source and methods

Incidence



Country-specific data source: No data  
 Method: No data: the rates are those of neighbouring countries or registries in the same area

Mortality

Country-specific data source: No data  
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

